Zai licenses preclinical<span class="*Red-type+bold"> cancer candidate from Sanofi

Zai Laboratory Inc. (Shanghai, China) obtained an exclusive, worldwide license from Sanofi (Euronext:SAN; NYSE:SNY) to develop, manufacture and commercialize a preclinical multi-kinase inhibitor for oncology indications including non-small cell lung cancer (NSCLC). Sanofi is eligible for undisclosed development and regulatory milestones, plus tiered sales royalties. ...